Penn Medicine and Candel Therapeutics partner to pursue potential solid tumor CAR-T cell therapy

Penn Medicine’s Center for Cellular Immunotherapies has entered into a cancer treatment collaboration with suburban Boston-based Candel Therapeutics.

Through the partnership, Penn researchers will study the impact of novel viral immunotherapies based on herpes simplex virus (HSV) vectors provided by Candel with hopes of augmenting the effects of Penn’s CAR-T cell therapies in solid tumor models.  The Penn research team is led by Neil C. Sheppard, D.Phil, adjunct associate professor of pathology and laboratory medicine in the Perelman School of Medicine and director of the T-Cell Engineering Lab within Penn’s Center for Cellular Immunotherapies.

Per a Philadelphia Business Journal, Paul Peter Tak, MD, PhD, Candel’s CEO, described his company’s partnership with Penn as “a first step towards evaluating the impact of innovative viral immunotherapies in combination with CAR-T cells.”

You can learn more about this exciting new partnership here in the Philadelphia Business Journal and here in EndPoints.

Skip to content